FeesSafety
Pluang+

Bitcoin shows signs of recovery above $80,000 as crypto adoption grows, signaling a mild bear market end.

Market News
08 Nov 2026, 18:20 WIB
Tokenpost
View Source
Bullish
Bitcoin shows signs of recovery above $80,000 as crypto adoption grows, signaling a mild bear market end.

Bitcoin may be emerging from its mildest bear market, with prices recovering above $80,000 and increased adoption of crypto technology. Kraken co-CEO Dave Ripley noted that despite being mid-cycle in a typical four-year bear market, current conditions feel different, suggesting the downturn has passed. Financial institutions are now embracing open crypto networks, expanding into areas like stablecoins and tokenized equities. Kraken's parent company, Payward, is diversifying its offerings across assets and geographies, aiming to reduce volatility and support growth, with plans to expand banking services in Europe and a confidential IPO filing underway.

Bitcoin's potential exit from its mildest bear market is the subject, with Pluang market data providing context for readers. As of Nov 08, 2026 23:21 WIB, 13 out of 50 major cryptocurrencies rose while 36 fell. Among notable movers, THETA traded at Rp2.561 with a 1-day change of -2.99% and a typical hold time of 78 days, while SNX was priced at Rp2.927, down 2.98%, and VET stood at Rp93 with a 2.91% decline and a typical hold time of 149 days.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
1 hour ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
1 hour ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
1 hour ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
1 hour ago
Anthropic's $895B AI contract commitments pose major risks to suppliers and Wall Street debt markets.

Anthropic's $895B AI contract commitments pose major risks to suppliers and Wall Street debt markets.

Anthropic has committed $895.4 billion to future AI infrastructure contracts, heavily impacting suppliers like Broadcom, Alphabet, and Amazon, who are already burning cash to meet these obligations. This massive spending commitment, revealed in Anthr...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App